10-Q: Bioxytran Reports Q2 2024 Results: Focus Remains on Funding and Drug Development

Bioxytran, a clinical-stage pharmaceutical company, announced its Q2 2024 results, highlighting ongoing efforts to secure funding for continued drug development and regulatory approvals.

Summary

• Bioxytran, Inc., a clinical-stage pharmaceutical company, released its unaudited condensed consolidated financial statements for the second quarter of 2024.
• The company is focused on developing therapeutic drugs for hypoxia and viral diseases.
• Bioxytran has incurred cumulative net losses of $16,959,641 as of June 30, 2024, and has not yet generated any revenues.
• The company's cash reserves are limited, with $13,522 in cash as of June 30, 2024, and a negative working capital of $1,214,987.
• Management is actively seeking additional capital through private placements and public offerings to fund operations and drug development.
• A Joint Venture Agreement was entered into with the Heme Foundation and NDPD Pharma, Inc. on July 15, 2024, to develop a Universal Oxygen Carrier (UOC).
• The development cost for UOC is estimated to be between $20 to $25 million over a 3 to 5-year period.
• The company's disclosure controls and procedures were deemed ineffective due to a material weakness in the segregation of duties in the company's internal controls.
• The company's management believes that an additional $3,700,000 is required to continue business operations for the next 15 months.

Sentiment

Score: 4

Explanation: The document presents a mixed sentiment. While there are positive developments such as the Joint Venture Agreement and potential of the UOC, the company's financial position is weak, and there are concerns about its ability to continue as a going concern. The ineffective disclosure controls and procedures also raise concerns.

Positives

• The company entered into a Joint Venture Agreement with the Heme Foundation and NDPD Pharma, Inc. to develop a Universal Oxygen Carrier (UOC).
• The UOC has shown no known side-effects in any studies.
• The UOC is shelf-stable, requiring no refrigeration and with a storage life of 5+ years in liquid or dehydrated form.
• Management has taken a 67% compensation cut for the remainder of 2024, or until the Company is listed on a major national stock exchange, whichever comes first.

Negatives

• The company has incurred cumulative net losses of $16,959,641 as of June 30, 2024.
• The company's cash reserves are limited, with $13,522 in cash as of June 30, 2024.
• The company has a negative working capital of $1,214,987 as of June 30, 2024.
• The company's disclosure controls and procedures were deemed ineffective due to a material weakness in the segregation of duties in the company's internal controls.

Risks

• The company's ability to continue as a going concern is dependent on obtaining additional financing.
• Failure to obtain additional financing could require the company to cease operations.
• The company's convertible loans outstanding at a total face value of $805,000 could lead to substantial dilution to shareholders if converted.
• The affiliate has the option to convert shares in the Subsidiary into a 17.5% ownership in the Company, which could result in notable dilution to shareholders.
• The company's small accounting staff may prevent adequate controls in the future, such as segregation of duties, due to the cost/benefit of such remediation.

Future Outlook

The company plans to seek additional capital through private placements and public offerings of its Common Stock to fund its operations and drug development. The company is also focused on advancing the development of its Universal Oxygen Carrier (UOC) through a joint venture.

Management Comments

• Management plans to seek additional capital through private placements and public offerings of its Common Stock.
• Management believes that an additional $3,700,000 is required to continue business operations for the next 15 months.

Industry Context

Bioxytran operates in the competitive pharmaceutical industry, specifically focusing on therapeutic molecules for stroke and viral diseases. The company's development of the Acellular Oxygen Carrier (AOC) and ProLectin positions it within the broader market for hypoxia and antiviral treatments. The company's success depends on its ability to secure funding, navigate regulatory approvals, and demonstrate the efficacy and safety of its products.

Comparison to Industry Standards

• It is difficult to compare Bioxytran to industry standards due to its early clinical stage and lack of revenue.
• Many comparable companies are private or have different business models.
• However, the company's focus on hypoxia and antiviral treatments aligns with broader industry trends in these areas.
• The estimated development cost of $20 to $25 million for UOC is within the typical range for early-stage drug development programs.
• The company's reliance on convertible debt and equity financing is common for small, clinical-stage pharmaceutical companies.

Related Party Transactions

• The Company holds License Agreements for a medical device and a compound with two affiliated companies where the beneficial ownership includes the Company's officers.
• The Company had at June 30, 2024, loan agreements calling for an 8 % interest with two of its affiliates for a total value of $ 70,974 with an accrued interest of $ 2,515 .
• NDPD is an affiliate of Bioxytran, and the beneficial ownership includes the Company's officers.

Stakeholder Impact

• Shareholders face potential dilution from convertible notes and equity offerings.
• Employees face uncertainty due to the company's financial instability.
• Customers and suppliers are affected by the company's ability to continue operations and develop its products.
• Creditors face risk due to the company's limited cash reserves and negative working capital.

Next Steps

• The company intends to raise additional capital through private placements and public offerings of its Common Stock.
• The company intends to proceed with a 14-day repeated dose toxicity study using New Zealand Rabbits and Wistar Rats as funding permits.
• The company will continue the study by filing an Emergency IND with the FDA in the fourth quarter of 2024, provided adequate funding is obtained.
• An IND is currently under preparation to be filed with the FDA in the third quarter of 2024.

Key Dates

Keywords

Bioxytran, Pharmalectin, Universal Oxygen Carrier, UOC, BXT-25, Acellular Oxygen Carrier, Hypoxia, Drug Development, Clinical Stage, Convertible Notes, Joint Venture, Financial Results